Economic consequences of the implementation of national screening program for chronic HCV infection-Reference-Cited by-同舟云学术

Economic consequences of the implementation of national screening program for chronic HCV infection

Published:2019-09-13 Issue:4 Volume:20 Page:397-404
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Dimitrova Maria¹,Tachkov Konstantin¹,Petrova Guenka¹

Affiliation:

1. Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University – Sofia, Sofia, Bulgaria

Funder

not funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2019.1666000

Reference26 articles.

1. Evolving epidemiology of hepatitis C virus

2. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

3. WHO: guidelines for screening care and treatment of persons with chronic hepatitis C infection. Updated version 2016, ISBN 978 92 4 154961 5. [cited 2019 Jan]. Available from: https://apps.who.int/iris/bitstream/handle/10665/205035/9789241549615_eng.pdf;jsessionid=7DD81A30D03F26C35EA93715F21FE322?sequence=1.

4. Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays

5. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations;Applied Health Economics and Health Policy;2021-12-06